---
authors:
- ReactomeTeam
description: Interleukin-4 (IL4) is a principal regulatory cytokine during the immune
  response, crucially important in allergy and asthma (Nelms et al. 1999). When resting
  T cells are antigen-activated and expand in response to Interleukin-2 (IL2), they
  can differentiate as Type 1 (Th1) or Type 2 (Th2) T helper cells. The outcome is
  influenced by IL4. Th2 cells secrete IL4, which both stimulates Th2 in an autocrine
  fashion and acts as a potent B cell growth factor to promote humoral immunity (Nelms
  et al. 1999). <br><br>Interleukin-13 (IL13) is an immunoregulatory cytokine secreted
  predominantly by activated Th2 cells. It is a key mediator in the pathogenesis of
  allergic inflammation. IL13 shares many functional properties with IL4, stemming
  from the fact that they share a common receptor subunit. IL13 receptors are expressed
  on human B cells, basophils, eosinophils, mast cells, endothelial cells, fibroblasts,
  monocytes, macrophages, respiratory epithelial cells, and smooth muscle cells, but
  unlike IL4, not T cells. Thus IL13 does not appear to be important in the initial
  differentiation of CD4 T cells into Th2 cells, rather it is important in the effector
  phase of allergic inflammation (Hershey et al. 2003).  IL4 and IL13 induce â€œalternative
  activationâ€� of macrophages, inducing an anti-inflammatory phenotype by signaling
  through IL4R alpha in a STAT6 dependent manner. This signaling plays an important
  role in the Th2 response, mediating anti-parasitic effects and aiding wound healing
  (Gordon & Martinez 2010, Loke et al. 2002)  There are two types of IL4 receptor
  complex (Andrews et al. 2006). Type I IL4R (IL4R1) is predominantly expressed on
  the surface of hematopoietic cells and consists of IL4R and IL2RG, the common gamma
  chain. Type II IL4R (IL4R2) is predominantly expressed on the surface of nonhematopoietic
  cells, it consists of IL4R and IL13RA1 and is also the type II receptor for IL13.
  (Obiri et al. 1995, Aman et al. 1996, Hilton et al. 1996, Miloux et al. 1997, Zhang
  et al. 1997). The second receptor for IL13 consists of IL4R and Interleukin-13 receptor
  alpha 2 (IL13RA2), sometimes called Interleukin-13 binding protein (IL13BP). It
  has a high affinity receptor for IL13 (Kd = 250 pmol/L) but is not sufficient to
  render cells responsive to IL13, even in the presence of IL4R (Donaldson et al.
  1998). It is reported to exist in soluble form (Zhang et al. 1997) and when overexpressed
  reduces JAK-STAT signaling (Kawakami et al. 2001). It's function may be to prevent
  IL13 signalling via the functional IL4R:IL13RA1 receptor. IL13RA2 is overexpressed
  and enhances cell invasion in some human cancers (Joshi & Puri 2012).<br><br>The
  first step in the formation of IL4R1 (IL4:IL4R:IL2RB) is the binding of IL4 with
  IL4R (Hoffman et al. 1995, Shen et al. 1996, Hage et al. 1999). This is also the
  first step in formation of IL4R2 (IL4:IL4R:IL13RA1). After the initial binding of
  IL4 and IL4R, IL2RB binds (LaPorte et al. 2008), to form IL4R1. Alternatively, IL13RA1
  binds, forming IL4R2. In contrast, the type II IL13 complex (IL13R2) forms with
  IL13 first binding to IL13RA1 followed by recruitment of  IL4R (Wang et al. 2009).<br><br>Crystal
  structures of the IL4:IL4R:IL2RG, IL4:IL4R:IL13RA1 and IL13:IL4R:IL13RA1 complexes
  have been determined (LaPorte et al. 2008). Consistent with these structures, in
  monocytes IL4R is tyrosine phosphorylated in response to both IL4 and IL13 (Roy
  et al. 2002, Gordon & Martinez 2010) while IL13RA1 phosphorylation is induced only
  by IL13 (Roy et al. 2002, LaPorte et al. 2008) and IL2RG phosphorylation is induced
  only by IL4 (Roy et al. 2002).<br><br>Both IL4 receptor complexes signal through
  Jak/STAT cascades. IL4R is constitutively-associated with JAK2 (Roy et al. 2002)
  and associates with JAK1 following binding of IL4 (Yin et al. 1994) or IL13 (Roy
  et al. 2002). IL2RG constitutively associates with JAK3 (Boussiotis et al. 1994,
  Russell  et al. 1994). IL13RA1 constitutively associates with TYK2 (Umeshita-Suyama
  et al. 2000, Roy et al. 2002, LaPorte et al. 2008, Bhattacharjee et al. 2013). <br><br>IL4
  binding to IL4R1 leads to phosphorylation of JAK1 (but not JAK2) and STAT6 activation
  (Takeda et al. 1994, Ratthe et al. 2007, Bhattacharjee et al. 2013). <br><br>IL13
  binding increases activating tyrosine-99 phosphorylation of IL13RA1 but not that
  of IL2RG. IL4 binding to IL2RG leads to its tyrosine phosphorylation (Roy et al.
  2002). IL13 binding to IL4R2 leads to TYK2 and JAK2 (but not JAK1) phosphorylation
  (Roy & Cathcart 1998, Roy et al. 2002).<br><br>Phosphorylated TYK2 binds and phosphorylates
  STAT6 and possibly STAT1 (Bhattacharjee et al. 2013).  <br><br>A second mechanism
  of signal transduction activated by IL4 and IL13 leads to the insulin receptor substrate
  (IRS) family (Kelly-Welch et al. 2003). IL4R1 associates with insulin receptor substrate
  2 and activates the PI3K/Akt and Ras/MEK/Erk pathways involved in cell proliferation,
  survival and translational control. IL4R2 does not associate with insulin receptor
  substrate 2 and consequently the PI3K/Akt and Ras/MEK/Erk pathways are not activated
  (Busch-Dienstfertig & GonzÃ¡lez-RodrÃ­guez 2013).  View original pathway at [http://www.reactome.org/PathwayBrowser/#DIAGRAM=6785807
  Reactome].
last-edited: 2021-01-25
organisms:
- Homo sapiens
redirect_from:
- /index.php/Pathway:WP4066
- /instance/WP4066
revision: null
schema-jsonld:
- '@context': https://schema.org/
  '@id': https://wikipathways.github.io/pathways/WP4066.html
  '@type': Dataset
  creator:
    '@type': Organization
    name: WikiPathways
  description: Interleukin-4 (IL4) is a principal regulatory cytokine during the immune
    response, crucially important in allergy and asthma (Nelms et al. 1999). When
    resting T cells are antigen-activated and expand in response to Interleukin-2
    (IL2), they can differentiate as Type 1 (Th1) or Type 2 (Th2) T helper cells.
    The outcome is influenced by IL4. Th2 cells secrete IL4, which both stimulates
    Th2 in an autocrine fashion and acts as a potent B cell growth factor to promote
    humoral immunity (Nelms et al. 1999). <br><br>Interleukin-13 (IL13) is an immunoregulatory
    cytokine secreted predominantly by activated Th2 cells. It is a key mediator in
    the pathogenesis of allergic inflammation. IL13 shares many functional properties
    with IL4, stemming from the fact that they share a common receptor subunit. IL13
    receptors are expressed on human B cells, basophils, eosinophils, mast cells,
    endothelial cells, fibroblasts, monocytes, macrophages, respiratory epithelial
    cells, and smooth muscle cells, but unlike IL4, not T cells. Thus IL13 does not
    appear to be important in the initial differentiation of CD4 T cells into Th2
    cells, rather it is important in the effector phase of allergic inflammation (Hershey
    et al. 2003).  IL4 and IL13 induce â€œalternative activationâ€� of macrophages,
    inducing an anti-inflammatory phenotype by signaling through IL4R alpha in a STAT6
    dependent manner. This signaling plays an important role in the Th2 response,
    mediating anti-parasitic effects and aiding wound healing (Gordon & Martinez 2010,
    Loke et al. 2002)  There are two types of IL4 receptor complex (Andrews et al.
    2006). Type I IL4R (IL4R1) is predominantly expressed on the surface of hematopoietic
    cells and consists of IL4R and IL2RG, the common gamma chain. Type II IL4R (IL4R2)
    is predominantly expressed on the surface of nonhematopoietic cells, it consists
    of IL4R and IL13RA1 and is also the type II receptor for IL13. (Obiri et al. 1995,
    Aman et al. 1996, Hilton et al. 1996, Miloux et al. 1997, Zhang et al. 1997).
    The second receptor for IL13 consists of IL4R and Interleukin-13 receptor alpha
    2 (IL13RA2), sometimes called Interleukin-13 binding protein (IL13BP). It has
    a high affinity receptor for IL13 (Kd = 250 pmol/L) but is not sufficient to render
    cells responsive to IL13, even in the presence of IL4R (Donaldson et al. 1998).
    It is reported to exist in soluble form (Zhang et al. 1997) and when overexpressed
    reduces JAK-STAT signaling (Kawakami et al. 2001). It's function may be to prevent
    IL13 signalling via the functional IL4R:IL13RA1 receptor. IL13RA2 is overexpressed
    and enhances cell invasion in some human cancers (Joshi & Puri 2012).<br><br>The
    first step in the formation of IL4R1 (IL4:IL4R:IL2RB) is the binding of IL4 with
    IL4R (Hoffman et al. 1995, Shen et al. 1996, Hage et al. 1999). This is also the
    first step in formation of IL4R2 (IL4:IL4R:IL13RA1). After the initial binding
    of IL4 and IL4R, IL2RB binds (LaPorte et al. 2008), to form IL4R1. Alternatively,
    IL13RA1 binds, forming IL4R2. In contrast, the type II IL13 complex (IL13R2) forms
    with IL13 first binding to IL13RA1 followed by recruitment of  IL4R (Wang et al.
    2009).<br><br>Crystal structures of the IL4:IL4R:IL2RG, IL4:IL4R:IL13RA1 and IL13:IL4R:IL13RA1
    complexes have been determined (LaPorte et al. 2008). Consistent with these structures,
    in monocytes IL4R is tyrosine phosphorylated in response to both IL4 and IL13
    (Roy et al. 2002, Gordon & Martinez 2010) while IL13RA1 phosphorylation is induced
    only by IL13 (Roy et al. 2002, LaPorte et al. 2008) and IL2RG phosphorylation
    is induced only by IL4 (Roy et al. 2002).<br><br>Both IL4 receptor complexes signal
    through Jak/STAT cascades. IL4R is constitutively-associated with JAK2 (Roy et
    al. 2002) and associates with JAK1 following binding of IL4 (Yin et al. 1994)
    or IL13 (Roy et al. 2002). IL2RG constitutively associates with JAK3 (Boussiotis
    et al. 1994, Russell  et al. 1994). IL13RA1 constitutively associates with TYK2
    (Umeshita-Suyama et al. 2000, Roy et al. 2002, LaPorte et al. 2008, Bhattacharjee
    et al. 2013). <br><br>IL4 binding to IL4R1 leads to phosphorylation of JAK1 (but
    not JAK2) and STAT6 activation (Takeda et al. 1994, Ratthe et al. 2007, Bhattacharjee
    et al. 2013). <br><br>IL13 binding increases activating tyrosine-99 phosphorylation
    of IL13RA1 but not that of IL2RG. IL4 binding to IL2RG leads to its tyrosine phosphorylation
    (Roy et al. 2002). IL13 binding to IL4R2 leads to TYK2 and JAK2 (but not JAK1)
    phosphorylation (Roy & Cathcart 1998, Roy et al. 2002).<br><br>Phosphorylated
    TYK2 binds and phosphorylates STAT6 and possibly STAT1 (Bhattacharjee et al. 2013).  <br><br>A
    second mechanism of signal transduction activated by IL4 and IL13 leads to the
    insulin receptor substrate (IRS) family (Kelly-Welch et al. 2003). IL4R1 associates
    with insulin receptor substrate 2 and activates the PI3K/Akt and Ras/MEK/Erk pathways
    involved in cell proliferation, survival and translational control. IL4R2 does
    not associate with insulin receptor substrate 2 and consequently the PI3K/Akt
    and Ras/MEK/Erk pathways are not activated (Busch-Dienstfertig & GonzÃ¡lez-RodrÃ­guez
    2013).  View original pathway at [http://www.reactome.org/PathwayBrowser/#DIAGRAM=6785807
    Reactome].
  keywords:
  - 4xPalmC-CD36
  - ADP
  - 'AKT1 '
  - 'AKT1 gene '
  - 'ALOX15 '
  - 'ALOX15 gene '
  - 'ALOX5 '
  - 'ALOX5 gene '
  - 'ANXA1 '
  - 'ANXA1 gene '
  - ATP
  - 'BATF '
  - 'BATF gene '
  - 'BCL2 '
  - 'BCL2 gene '
  - BCL2 gene, BCL2L1
  - 'BCL2L1 '
  - 'BCL2L1 gene '
  - 'BCL6 '
  - 'BCL6 gene '
  - 'BIRC5 '
  - 'BIRC5 gene '
  - Bcl-2/Bcl-X(L)
  - 'CCL11 '
  - 'CCL11 gene '
  - 'CCL2 '
  - 'CCL2 gene '
  - 'CCL22 gene '
  - 'CCL22(25-93) '
  - 'CCND1 '
  - 'CCND1 gene '
  - CD36 gene
  - 'CDKN1A '
  - 'CDKN1A gene '
  - 'CEBPD '
  - 'CEBPD gene '
  - 'COL1A2 '
  - 'COL1A2 gene '
  - 'F13A1 gene '
  - FASLG gene
  - FASLG(1-281)
  - 'FCER2 gene '
  - 'FCER2(1-321) '
  - 'FGF2 gene '
  - 'FGF2(10-155) '
  - 'FN1 gene '
  - 'FN1(32-2386) '
  - 'FOS '
  - 'FOS gene '
  - 'FOXO1 '
  - 'FOXO1 gene '
  - 'FOXO3 '
  - 'FOXO3 gene '
  - 'FSCN1 '
  - 'FSCN1 gene '
  - GATA3
  - GATA3 gene
  - 'HGF gene '
  - 'HGF(32-494) '
  - 'HIF1A '
  - 'HIF1A gene '
  - HMOX1
  - HMOX1 gene
  - 'HSP90AA1 '
  - 'HSP90AA1 gene '
  - HSP90B1
  - 'HSPA8 '
  - 'HSPA8 gene '
  - HSPA8 gene, ALOX15
  - HSPA8, ALOX15
  - 'ICAM1 '
  - 'ICAM1 gene '
  - 'IGHE '
  - 'IGHE gene '
  - 'IGHG1 '
  - 'IGHG1 gene '
  - 'IGHG4 '
  - 'IGHG4 gene '
  - 'IL10 '
  - 'IL10 gene '
  - 'IL12A '
  - 'IL12A gene '
  - 'IL12B '
  - 'IL12B gene '
  - IL13
  - 'IL13 '
  - IL13-bound
  - IL13-downregulated
  - IL13-upregulated
  - IL13:IL13RA2
  - IL13:IL13RA:TYK2
  - IL13:IL13RA:TYK2:IL4R:JAK2
  - IL13:IL13RA:TYK2:IL4R:JAK2:JAK1
  - IL13RA1
  - 'IL13RA1 '
  - IL13RA1:TYK2
  - IL13RA2
  - 'IL13RA2 '
  - 'IL17A '
  - 'IL17A gene '
  - 'IL17F '
  - 'IL17F gene '
  - 'IL18 gene '
  - IL18 gene, ALOX5
  - 'IL18(1-193) '
  - IL18, ALOX5
  - 'IL1A gene '
  - 'IL1B '
  - 'IL1B gene '
  - 'IL1B,Myr82K-Myr83K-IL1A '
  - 'IL23A '
  - 'IL23A gene '
  - 'IL23R '
  - 'IL23R gene '
  - IL2RG
  - 'IL2RG '
  - IL2RG:JAK3
  - IL4
  - 'IL4 '
  - IL4, IL13
  - IL4,IL13-downregulated extracellular proteins
  - IL4,IL13-downregulated genes for extracellular proteins
  - IL4,IL13-upregulated
  - IL4:IL4R:JAK2
  - IL4:IL4R:JAK2:IL13RA1:TYK2
  - IL4:IL4R:JAK2:IL13RA:TYK2:SOCS5,(SOCS1)
  - IL4:IL4R:JAK2:IL2RG:JAK3
  - IL4:IL4R:JAK2:IL2RG:JAK3:JAK1
  - IL4:p-Y-IL4R:JAK2:p-Y-IL2RG:JAK3:p-Y-JAK1
  - IL4:p-Y-IL4R:JAK2:p-Y-IL2RG:JAK3:p-Y-JAK1:STAT3,STAT6
  - IL4:p-Y-IL4R:JAK2:p-Y-IL2RG:JAK3:p-Y-JAK1:p-Y705-STAT3,p-Y641-STAT6
  - IL4R
  - 'IL4R '
  - 'IL4R gene '
  - IL4R:JAK2
  - 'IL6 '
  - 'IL6 gene '
  - 'IL6R '
  - 'IL6R gene '
  - 'IL8 '
  - 'IL8 gene '
  - 'IRF4 '
  - 'IRF4 gene '
  - 'ITGAM '
  - 'ITGAM gene '
  - 'ITGAX '
  - 'ITGAX gene '
  - 'ITGB1 '
  - 'ITGB1 Gene '
  - 'ITGB2 '
  - 'ITGB2  gene '
  - JAK1
  - 'JAK1 '
  - JAK2
  - 'JAK2 '
  - JAK3
  - 'JAK3 '
  - JAK3 inhibitors
  - JAK3:JAK3 inhibitors
  - 'JUNB '
  - 'JUNB gene '
  - 'LAMA5 '
  - 'LAMA5 gene '
  - 'LBP '
  - 'LBP gene '
  - 'LCN2 '
  - 'LCN2 gene '
  - 'LIF '
  - 'LIF gene '
  - MAOA
  - MAOA gene
  - 'MCL1 '
  - 'MCL1 gene '
  - 'MMP1 gene '
  - 'MMP1(84-469) '
  - 'MMP2 gene '
  - 'MMP2(110-660) '
  - 'MMP3 gene '
  - 'MMP3(100-477) '
  - 'MMP9 gene '
  - 'MMP9(107-707) '
  - 'MUC1 gene '
  - 'MUC1(24-1255) '
  - 'MYC '
  - 'MYC gene '
  - 'Myr82K-Myr83K-IL1A '
  - 'NANOG '
  - 'NANOG gene '
  - 'NDN '
  - 'NDN gene '
  - NDN gene, TP53 gene
  - NDN, TP53
  - 'NOS2 '
  - 'NOS2 gene '
  - 'OPRD1 '
  - 'OPRD1 gene '
  - 'OPRM1 '
  - 'OPRM1 gene '
  - 'OSM '
  - 'OSM gene '
  - 'PIK3R1 '
  - 'PIK3R1 gene '
  - 'PIM1 '
  - 'PIM1 gene '
  - 'POMC gene '
  - 'POMC(138-176) '
  - 'POU2F1 '
  - 'POU2F1 gene '
  - PTGS2
  - PTGS2 gene
  - 'RHOU '
  - 'RHOU gene '
  - 'RORA '
  - 'RORA gene '
  - 'RORC '
  - 'RORC gene '
  - 'S1PR1 '
  - 'S1PR1 gene '
  - 'SAA1 gene '
  - 'SAA1(19-122) '
  - SOCS1
  - 'SOCS1 '
  - SOCS1 gene
  - 'SOCS3 '
  - 'SOCS3 gene '
  - 'SOCS5 '
  - SOCS5,(SOCS1)
  - 'SOX2 '
  - 'SOX2 gene '
  - 'STAT1 '
  - 'STAT1 gene '
  - STAT1,STAT3,STAT6
  - 'STAT3 '
  - STAT3,STAT6
  - STAT3-upregulated
  - 'STAT6 '
  - STAT6 upregulated
  - 'TGFB1 gene '
  - 'TGFB1(30-278) '
  - 'TIMP1 '
  - 'TIMP1 gene '
  - 'TNF gene '
  - 'TNF(77-233) '
  - 'TNFRSF1B '
  - 'TNFRSF1B gene '
  - 'TP53 '
  - 'TP53 gene '
  - 'TWIST1 '
  - 'TWIST1 gene '
  - TYK2
  - 'TYK2 '
  - 'VCAM1 '
  - 'VCAM1 gene '
  - 'VEGFA '
  - 'VEGFA gene '
  - 'VIM '
  - 'VIM gene '
  - 'ZEB1 '
  - 'ZEB1 gene '
  - 'baricitinib '
  - cytosolic proteins
  - dimer
  - dimer,p-Y641-STAT6
  - dimer,p-Y705-STAT3
  - extracellular
  - extracellular genes
  - 'factor XIII A chain '
  - gene
  - genes for
  - genes for cytosolic
  - genes for nuclear
  - genes for plasma
  - membrane proteins
  - nuclear proteins
  - 'p-Y-IL13RA1 '
  - 'p-Y-IL2RG '
  - 'p-Y-IL4R '
  - 'p-Y-JAK1 '
  - 'p-Y-TYK2 '
  - 'p-Y1007-JAK2 '
  - p-Y614-STAT6 dimer
  - 'p-Y641-STAT6 '
  - p-Y641-STAT6 dimer
  - p-Y701-STAT1
  - 'p-Y701-STAT1 '
  - p-Y701-STAT1,p-Y705-STAT3,p-Y641-STAT6
  - 'p-Y705-STAT3 '
  - p-Y705-STAT3 dimer
  - p-Y705-STAT3 dimer,
  - p-Y705-STAT3,p-Y641-STAT6
  - plasma membrane
  - protein genes
  - proteins
  - tyrosine-phosphorylated IL13 receptor type II with STAT1,STAT3,STAT6
  - tyrosine-phosphorylated IL13 receptor type II with phosphorylated STAT1,STAT3,STAT6
  - tyrosine-phosphorylated IL13R type II
  license: CC0
  name: Interleukin-4 and Interleukin-13 signaling
seo: CreativeWork
title: Interleukin-4 and Interleukin-13 signaling
wpid: WP4066
---